← Back to screener

Alto Neuroscience, Inc. ANRO

Rank #1603 · NYSE · $0.8B market cap
Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.
Score
45.7
P/E
-12.9
P/B
-11.07
ROE
85.7%
Op. Margin
–%
Debt Ratio
-36%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -12.9x, P/B -11.07x. Ranks in the top 91% of the universe.

Profitability ★★★★★
Excellent

ROE 85.7%. Ranks in the top 4% of the universe.

Safety ★★★★★
Excellent

Debt ratio -36%. Ranks in the top 7% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2024–$-0.0B$-0.0B$-0.0B–-44
2025–$-0.1B$-0.1B$-0.1B–-36

← See the full screener